Rovalpituzumab tesirine,一种靶向DLL3的抗体药物偶联物,用于复发性小细胞肺癌:首次人体、首创类、开放标签、1期研究
该1期开放标签研究在美国10家癌症中心纳入82例患者(74例小细胞肺癌),评估靶向DLL3的抗体药物偶联物rovalpituzumab tesirine的安全性和活性。最大耐受剂量为0.4 mg/kg每3周,推荐2期剂量为0.3 mg/kg每6周;在有效剂量下,60例可评估患者中11例(18%)确认客观缓解,高DLL3表达患者中10例(38%)缓解。
要点
- 最大耐受剂量为0.4 mg/kg每3周,推荐2期剂量为0.3 mg/kg每6周。
- 有效剂量下60例可评估患者中11例(18%)确认客观缓解。
- 高DLL3表达(≥50%肿瘤细胞)患者中10例(38%)确认客观缓解。
核心结论
- Rovalpituzumab tesirine单药显示出令人鼓舞的抗肿瘤活性,安全性可控。
- 有必要在DLL3表达的恶性疾病中进一步开发rovalpituzumab tesirine。
研究设计与样本
- 在美国10家癌症中心开展的1期开放标签研究。
- 纳入年龄≥18岁、组织学或细胞学确诊的小细胞肺癌或大细胞神经内分泌肿瘤患者,具有可测量进展期疾病(RECIST 1.1),既往接受过1或2种化疗方案(包括铂类方案)。
- 患者分配至剂量递增或扩展队列,rovalpituzumab tesirine静脉给药剂量范围0.05 mg/kg至0.8 mg/kg,每3周或每6周一次,随后研究0.3 mg/kg和0.4 mg/kg每6周及0.2 mg/kg每3周方案。
- 2013年7月22日至2015年8月10日共入组82例患者,包括74例小细胞肺癌和8例大细胞神经内分泌癌,所有患者至少接受一剂rovalpituzumab tesirine。
- 主要目标为评估安全性(包括最大耐受剂量和剂量限制性毒性),主要活性终点为意向治疗分析中的客观缓解。
主要发现
- 剂量限制性毒性出现在0.8 mg/kg每3周剂量,包括4级血小板减少(该剂量水平2例中2例)和4级肝功能检查异常(1例)。
- 74例小细胞肺癌患者中最常见的≥3级治疗相关不良事件为血小板减少(8例[11%])、胸腔积液(6例[8%])和脂肪酶升高(5例[7%])。
- 74例患者中28例(38%)发生药物相关严重不良事件。
- 最大耐受剂量为0.4 mg/kg每3周;推荐2期剂量和方案为0.3 mg/kg每6周。
- 在有效剂量(0.2 mg/kg或0.4 mg/kg每3周,或0.3 mg/kg或0.4 mg/kg每6周)下,60例可评估患者中11例(18%)确认客观缓解,包括26例确认高DLL3表达(≥50%肿瘤细胞表达)患者中10例(38%)。
关键数值与推荐
- 剂量限制性毒性:0.8 mg/kg每3周时4级血小板减少(2/2例)和4级肝功能检查异常(1例)。
- 最大耐受剂量:0.4 mg/kg每3周。
- 推荐2期剂量和方案:0.3 mg/kg每6周。
- 有效剂量下确认客观缓解:60例可评估患者中11例(18%)。
- 高DLL3表达(≥50%肿瘤细胞)患者确认客观缓解:26例中10例(38%)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen. METHODS: We conducted a phase 1 open-label study at ten cancer centres in the USA. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed small-cell lung cancer or large-cell neuroendocrine tumours with progressive measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) previously treated with one or two chemotherapeutic regimens, including a platinum-based regimen. We assigned patients to dose-escalation or expansion cohorts, ranging from 0·05 mg/kg to 0·8 mg/kg rovalpituzumab tesirine intravenously every 3 weeks or every 6 weeks, followed by investigation of the dose schedules 0·3 mg/kg and 0·4 mg/kg every 6 weeks and 0·2 mg/kg every 3 weeks. Primary objectives were to assess the safety of rovalpituzumab tesirine, including the maximum tolerated dose and dose-limiting toxic effects. The primary activity endpoint was objective response by intention-to-treat analysis. This study is registered with ClinicalTrials.gov, number NCT01901653. The study is closed to enrolment; this report focuses on the cohort with small-cell lung cancer. FINDINGS: Between July 22, 2013, and Aug 10, 2015, 82 patients were enrolled, including 74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma, all of whom received at least one dose of rovalpituzumab tesirine. Dose-limiting toxic effects of rovalpituzumab tesirine occurred at a dose of 0·8 mg/kg every 3 weeks, including grade 4 thrombocytopenia (in two of two patients at that dose level) and grade 4 liver function test abnormalities (in one patient). The most frequent grade 3 or worse treatment-related adverse events in 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five [7%]). Drug-related serious adverse events occurred in 28 (38%) of 74 patients. The maximum tolerated dose of rovalpituzumab tesirine was 0·4 mg/kg every 3 weeks; the recommended phase 2 dose and schedule is 0·3 mg/kg every 6 weeks. At active doses of rovalpituzumab tesirine (0·2 mg/kg or 0·4 mg/kg every 3 weeks or 0·3 mg/kg or 0·4 mg/kg every 6 weeks), 11 (18%) of 60 assessable patients had a confirmed objective response. 11 (18%) of 60 assessable patients had a confirmed objective response, including ten (38%) of 26 patients confirmed to have high DLL3 expression (expression in 50% or more of tumour cells). INTERPRETATION: Rovalpituzumab tesirine shows encouraging single-agent antitumour activity with a manageable safety profile. Further development of rovalpituzumab tesirine in DLL3-expressing malignant diseases is warranted. FUNDING: Stemcentrx Inc.
引用
- Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2016. PMID: 27932068. doi:10.1016/S1470-2045(16)30565-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。